CIK 0001907108 · <br>Emerging growth company
Lexeo Therapeutics, Inc.
Sign in to watch- Ticker
- LXEO
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 854012572
- Phone
- (212) 547-9879
- Business address
- 345 PARK AVENUE SOUTH, FLOOR 6, NEW YORK, NY, 10010
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Planned sale Chief Executive Officer sold 55,000 shares at $5.69 ($313,137)
- 4 Grant or award Chief Executive Officer acquired 2,623 shares (grant or award)
- 4 Grant or award Chief Operating Officer acquired 5,930 shares (grant or award)
- 4 Open-market sale Chief Operating Officer sold 3,016 shares at $6.40 ($19,294)
- 4 Open-market sale Chief Executive Officer sold 10,173 shares at $6.38 ($64,924)
- 4/A Open-market sale Chief Operating Officer sold 721 shares at $9.27 ($6,684)
- 4 Grant or award Chief Medical Officer acquired 49,500 shares (grant or award)
- 4 Grant or award Chief Executive Officer acquired 161,665 shares (grant or award)
- 4 Grant or award Chief Operating Officer acquired 65,000 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 44,665 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Chief Executive Officer sold 1,127 shares at $9.27 ($10,447)
- 4 Open-market sale Chief Medical Officer sold 615 shares at $9.27 ($5,701)
- 4 Open-market sale Chief Development Officer sold 386 shares at $9.27 ($3,578)
- 4 Open-market sale Chief Legal Officer sold 549 shares at $9.27 ($5,089)
- 4 Open-market sale Chief Technical Officer sold 721 shares at $9.27 ($6,684)
- 4 Open-market sale Chief Development Officer sold 3,888 shares at an average $8.94 ($34,767)
- 4 Open-market sale Chief Legal Officer sold 3,526 shares at an average $8.94 ($31,530)
Page 2 of 7 · 121 filings